Who are Digoxin Antibodies Fab Fragments's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Digoxin immune fab, Magnesium sulfate and then Digoxin, Antizol, Cyanokit, Acetadote, Actidose Aqua.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/digoxin-antibodies-fab-fragments.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Digoxin Antibodies Fab Fragments — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Digoxin Antibodies Fab Fragments (Digoxin Antibodies Fab Fragments) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antidote; Digoxin-specific antibody fragment. Area: Cardiovascular.

marketed Antidote; Digoxin-specific antibody fragment Digoxin Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Digoxin Antibodies Fab Fragments (Digoxin Antibodies Fab Fragments) — University of Maryland, Baltimore. Digoxin-specific antibody fragments bind to and neutralize circulating digoxin, preventing its toxic cardiac effects.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Digoxin Antibodies Fab Fragments TARGET	Digoxin Antibodies Fab Fragments	University of Maryland, Baltimore	marketed	Antidote; Digoxin-specific antibody fragment	Digoxin
Digoxin immune fab	Digoxin immune fab	National Institute on Aging (NIA)	marketed	Antidote; Immunoglobulin fragment	Digoxin (cardiac glycoside)
Magnesium sulfate and then Digoxin	Magnesium sulfate and then Digoxin	Sunnybrook Health Sciences Centre	phase 3	Electrolyte supplement and cardiac glycoside combination	Na+/K+-ATPase (digoxin); magnesium-dependent ion channels and enzymes (magnesium sulfate)
Antizol	FOMEPIZOLE	Par Pharm Inc	marketed	Antidote [EPC]	Alcohol dehydrogenase	1997-01-01
Cyanokit	HYDROXOCOBALAMIN	Btg Intl	marketed	Antidote		1978-01-01
Acetadote	Acetylcysteine	Bristol-Myers Squibb	marketed	Antidote	Glutathione levels; reactive metabolite of acetaminophen	1963-01-01
Actidose Aqua	Actidose Aqua	National Institute of Allergy and Infectious Diseases (NIAID)	marketed	Adsorbent antidote

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2026-05-21 — Acetadote · 8148356 · Formulation · US
2031-07-21 — Acetadote · 9327028 · Method of Use · US
2032-04-06 — Acetadote · 8722738 · Method of Use · US
2032-05-08 — Acetadote · 8747894 · Formulation · US
2032-05-08 — Acetadote · 9561204 · Method of Use · US
2032-05-08 — Acetadote · 9427421 · Formulation · US

Sponsor landscape (Antidote; Digoxin-specific antibody fragment class)

University of Maryland, Baltimore · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Digoxin Antibodies Fab Fragments — Competitive Intelligence Brief. https://druglandscape.com/ci/digoxin-antibodies-fab-fragments. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab